31 maj: MT Højgaard Holding A/S: Martin Stig Solberg ny CFO i MT Højgaard..
01 jun: Brøndby IF – Niels Frederiksen ny cheftræner
31-05-2019 23:08:00

Envarsus XR® to be Subject of Upcoming Presentations at 2019 American Transplant Congress

Investor News no. 03/2019

To: NASDAQ Copenhagen A/S                                                

Copenhagen, Denmark, 31 May 2019

Envarsus XR® to be Subject of Upcoming Presentations at 2019 American Transplant Congress

Veloxis Pharmaceuticals (OMX: VELO) announced today that the Company’s product, Envarsus XR (tacrolimus extended-release tablets), will be the subject of two oral and fifteen poster presentations at the American Transplant Congress June 1st-5th, 2019 in Boston, Massachusetts, USA.  The presentations will highlight interesting data about Envarsus XR.

“We are encouraged by the tremendous amount of interest and commitment from the kidney transplant community in studying the potential benefits Envarsus XR and what this may offer our patients” said Ulf Meier-Kriesche, MD FAST, Chief Scientific Officer at Veloxis.

“Our momentum following the launch of the de novo indication earlier this year is strong going into the American Transplant Congress, and we are excited to spend the week with the transplant community focused on how we can continue to partner with them to improve the lives of kidney transplant patients” said Craig Collard, CEO of Veloxis.

Oral Presentations:

West-Thielke P, Maldonado A, Patel SJ, Stevens DR, Meier-Kriesche U, Brennan D. What’s in a High Dose? An Analysis of Tacrolimus Pharmacokinetic Parameters in Rapid Metabolizers [abstract]. Am J Transplant. 2019; 19 (suppl 3).

Cibrik D, West-Thielke P, Patel SJ, Stevens DR, Meier-Kriesche U. LCP-Tacrolimus (LCPT; Envarsus XR) Dosing Considerations in De Novo Kidney Transplant Recipients [abstract]. Am J Transplant. 2019; 19 (suppl 3).

Poster Presentations:

West-Thielke P, Oberholzer J, Wang Y. Microfluidic Study Analyzing the Effect of Immediate-Release and Extended-Release Tacrolimus on Islet Function [abstract]. Am J Transplant. 2019; 19 (suppl 3). 

Budde K, Bunnapradist S, Patel S, Stevens D, Meier-Kriesche U, Suwelack B. Dosing and Exposure over 2 Years with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac) in De Novo Kidney Transplantation [abstract]. Am J Transplant. 2019; 19 (suppl 3). 

Patel S, Khalil K, Lichvar A, Benedetti E, West-Thielke P. Time within Therapeutic Range: A Comparison of Three Tacrolimus Formulations within Ninety Days of Renal Transplant [abstract]. Am J Transplant. 2019; 19 (suppl 3).

Wolff R, Nasstrom A, Borscheid C, Martin C, Temelie A, Spong R, Keys D, Dunn TB. The Effect of a Novel Dosing Protocol for the De Novo Use of LCP Tacrolimus in Kidney Transplant Recipients Managed on a Steroid-Free Maintenance Immunosuppression Regimen [abstract]. Am J Transplant. 2019; 19 (suppl 3). 

Belfield KD, Malhotra D, Waleed M, Cohen EA. Conversion from Tacrolimus Immediate Release to Tacrolimus Extended Release (Envarsus XR®): A Real World Cohort Highlighting Dosing Variability among Patients [abstract]. Am J Transplant. 2019; 19 (suppl 3).

Budde K, Bunnapradist S, Patel SJ, Stevens DR, Meier-Kriesche U, Suwelack B. Early Tacrolimus Trough Attainment in De Novo Kidney Transplant Recipients Treated with LCP-Tacrolimus (LCPT) vs. Immediate-Release Tacrolimus (IR-Tac) [abstract]. Am J Transplant. 2019; 19 (suppl 3). 

Lineberger LR, Hollinger E, Kenyon N, Brokohf M, Alvey N. Evaluation of Envarsus XR in African American Kidney Transplant Recipients [abstract]. Am J Transplant. 2019; 19 (suppl 3). 

Spagnoletti G, Salerno MP, Gennaro FDe, Romagnoli J, Citterio F. Combination of Extended-Release Tacrolimus Plus Everolimus Once Daily in De Novo Kidney Transplant Recipients: ER-Tac vs LCPT [abstract]. Am J Transplant. 2019; 19 (suppl 3). 

Carthon CE, Hagopian JC, January SE, Gharabagi A, Santos RDelos, Horwedel TA. Delayed Achievement of Therapeutic Tacrolimus Levels with De Novo Extended-Release Tacrolimus Tablets and the Incidence of Rejection in Kidney Transplant Patients [abstract]. Am J Transplant. 2019; 19 (suppl 3). 

Horwedel TA, Carthon CE, January SE, Gharabagi A, Santos RDelos, Hagopian JC. A Naturalistic Study of De Novo Extended-Release Tacrolimus Tablets vs. Tacrolimus Immediate-Release Capsules in Kidney Transplant Recipients [abstract]. Am J Transplant. 2019; 19 (suppl 3). 

Hagopian J, Carthon C, January S, Gharabagi A, Santos RDelos, Horwedel T. Adverse Effect Differences between Tacrolimus-IR and LCP-Tacrolimus [abstract]. Am J Transplant. 2019; 19 (suppl 3). 

January S, Horwedel T, Hagopian J, Carthon C, Gharabagi A, Santos RDelos. Impact of Tacrolimus Formulation on Tacrolimus Level Coefficient of Variations [abstract]. Am J Transplant. 2019; 19 (suppl 3). 

Hagopian J, Carthon C, January S, Gharabagi A, Santos RDelos, Horwedel T. Difference in DSA Formation between Tacrolimus-XR and Tacrolimus-IR [abstract]. Am J Transplant. 2019; 19 (suppl 3). 

Condon A, Mujtaba M, Patel SJ, Stevens DR, Meier-Kriesche U. In Depth Look at Acute Rejections in LCP-Tacrolimus (LCPT; Envarsus XR) and Immediate-Release Tacrolimus (IR-Tac)-Treated De Novo Kidney Transplant Recipients [abstract]. Am J Transplant. 2019; 19 (suppl 3). 

Torabi J, Campbell A, Akalin E, Ajaimy M, Azzi Y, Pynadath C, Liriano-Ward L, Rocca JP, Graham JA. Utilization of LCP-Tacrolimus (ENVARSUS XR) in Simultaneous Pancreas and Kidney (SPK) Transplant Recipients [abstract]. Am J Transplant. 2019; 19 (suppl 3). 

The abstracts can be found at the 2019 American Transplant Congress

website: https://atcmeetingabstracts.com/

For more information, please contact:

 Craig A. Collard    Ira Duarte
 President & CEO  CFO
 Phone: + 1 919 591 3090  Phone: +1 919 591 3090
 Email: cac@veloxis.com  Email: idu@veloxis.com

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com.

About ENVARSUS XR® (tacrolimus extended-release tablets)

Indications and Usage

ENVARSUS XR is indicated for the prophylaxis of organ rejection in de novo kidney transplant patients in combination with other immunosuppressants.

ENVARSUS XR is also indicated for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants.

Important Safety Information for ENVARSUS XR

Boxed Warning:  Malignancies and Serious Infections

Increased risk for developing serious infections and malignancies with ENVARSUS XR or other immunosuppressants that may lead to hospitalization or death

Contraindications

ENVARSUS XR is contraindicated in patients with known hypersensitivity to tacrolimus.

Warnings and Precautions

Immunosuppressants, including ENVARSUS XR, increase the risk of developing lymphomas and other malignancies, particularly of the skin.

Post-transplant lymphoproliferative disorder (PTLD), associated with Epstein-Barr Virus (EBV), has been reported in immunosuppressed organ transplant patients.

Immunosuppressants, including ENVARSUS XR, increase the risk of developing bacterial, viral, fungal, and protozoal infections, including opportunistic infections. These infections may lead to serious, including fatal, outcomes.

ENVARSUS XR is not interchangeable or substitutable with tacrolimus extended-release capsules, tacrolimus immediate-release capsules or tacrolimus for oral suspension. 

Avoid the use of live attenuated vaccines during treatment with ENVARSUS XR. Inactivated vaccines noted to be safe for administration after transplantation may not be sufficiently immunogenic during treatment with ENVARSUS XR.

Cases of pure red cell aplasia (PRCA) have been reported in patients treated with tacrolimus. 

Adverse Reactions

De Novo kidney transplant patients: Most common adverse reactions (incidence ≥15%) reported with ENVARSUS XR are diarrhea, anemia, urinary tract infection, hypertension, tremor, constipation, diabetes mellitus, peripheral edema, hyperkalemia and headache.

Conversion of kidney transplant patients from immediate-release tacrolimus: Most common adverse reactions (incidence ≥10%) reported with ENVARSUS XR are diarrhea and blood creatinine increased.

For full Prescribing Information, see the US Package Insert and Medication Guide at 

www.envarsusxr.com

.

Attachment

Veloxis_logo - Color - Screen.png

Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 jul
GEN
Hmm. Det er med blandede følelser jeg for tid til anden følger med i Genmab trådende. Da Genmab s b..
16
17 jul
I:SP500
På verdensplan vil næsten ingen acceptere økonomisk tilbageholdenhed til fordel for klimaet. En mill..
16
18 jul
 
Foranlediget lidt af debatten i den sidste uges tid, kommer her fredagsjoken: En investor her på EI..
15
20 jul
TEVA
Henningmaria: Casen omkring Teva har ikke ændret sig fundamentalt blot folks følelser pga verserende..
13
17 jul
I:SP500
Tøjindustrien står for 10 % af udslippet af klimagasser ifølge The Angry Clean Energy Guy. Det er me..
13
17 jul
 
Jeg er kvinde på 75 år og har haft afdragsfrit lån i 10 år. Min tidligere bankrådgiver, som vdste mi..
12
16 jul
VELO
At der er nogle som hiver lidt gevinst hjem. Fred være med det. Velo skal op i en helt anden kurs, n..
12
15 jul
BAVA
Tænk engang, med alt det du skriver om Bavarian og ebola vaccinen, så skulle man tro, at du bare ved..
12
18 jul
VELO
Jeg havde ligeledes håbet der var mulighed for at supplere lidt længere nede, men nu hedder det nok ..
11
15 jul
VELO
At optimisme er et advarselstegn er da hul i hovedet. Det kommer an på hvad optimismen bunder i. For..
11

Aktier/tendens: Ørsted tiltænkt helterolle i positiv aktieåbning

19-07-2019 08:09:28
Der er positive nyheder fra både den danske energikoncern Ørsted og biotekselskabet Genmab som oplæg til fredagens danske aktiehandel, hvor markedet før åbningen generelt er bagud i forhold til den stigning de amerikanske aktier præsterede i torsdagens handel.Sammen med stigende futures for både det amerikanske S&P 500-indeks og for det tyske DAX-indeks tidlig fredag morgen peger det mod en positi..

Danske Bank Q2: Kundeflugten fortsætter i udfordret bank

18-07-2019 11:06:22
Kunder siger fortsat farvel til Danske Bank - omend i et langsommere tempo end tidligere. I andet kvartal valgte 4300 Nemkonto-kunder at slukke for den forbindelse til banken, hvor de første seks måneder samlet gav en kundeafgang på 13.600 Nemkonto-kunder svarende til 1 pct. af bankens Nemkonto-kundebase.Det er fortsat bankens hvidvasksag i Estland, der danner ringe i vandet - men også sagen om pr..

Aktier/tendens: Storbanker i fokus efter årle morgen-regnskaber

18-07-2019 08:26:01
Det er storbankerne Nordea og Danske Bank, der tager overskrifterne på det danske aktiemarked torsdag morgen og lægger retningen for børsens C25-indeks, der samtidig vil være presset af internationale kursfald.I USA lukkede Wall Street med fald i størrelsesordenen 0,4-0,7 pct., og i futuresmarkedet er faldene blevet uddybet med yderligere 0,3-0,5 pct.I Asien har investorernes mangel på begejstring..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. juli 2019 01:24:24
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190703.1 - EUROWEB1 - 2019-07-22 01:24:24 - 2019-07-22 01:24:24 - 1 - Website: OKAY